Skip to Main Content

Wajih Kidwai, MD, FACP

Associate Professor of Clinical Internal Medicine (Medical Oncology); Medical Director, Smilow Cancer Center; Medical Director, Smilow Cancer Center

Contact Information

Wajih Kidwai, MD, FACP

Mailing Address

  • Medical Oncology

    PO Box 208028

    New Haven, CT 06520-8028

    United States

Research Summary

I have had the honor and responsibility of working as the Medical Director of our office in Guilford and have maintained my position as it transitioned to Yale Smilow Guilford in 2012. As a result of great patient care development, quality of care and provision of state of the art cancer care here we have been able to expand our services with increased surgical and radiology services and by opening another office in Old Saybrook.

I work in collaboration with Radiation Oncology, which provides excellent service to the patients in our shoreline facility. We have worked together with Radiation Oncology on development of a busy Breast Cancer program with Radiation Oncology, breast surgery and breast radiology.

We have worked together on a number of studies here and are part of Clinical Research Working Group (CRWG) bringing research to the Smilow care centers.

I also attend and contribute to the Institutional Review Board (IRB) for Oncology protocols and have been actively participating since 2012. Having a very busy clinical practice, I usually use the weekend and off-hours to prepare for theses meetings and protocols. I have placed a number of patients on practice changing clinical trials resulting in presentations, papers and abstracts.

I am also honored to represent Yale University/Smilow Cancer Center in the hematopoietic panel of NCCN. I previously was also on the NCCN Panel of Neuroendocrine Tumors.

I have taken an active part in the Yale Quality program and in association with Dr. Anne Chiang and Dr. Kerin Adelson. In November of 2018 I presented our Goals of Care quality project at American Society of Clinical Oncology Palliative Care symposium in San Diego, CA.

I am also working closely with the Survivorship program and Breast cancer related Nutrition and Exercise related trials under the direction of Dr Tara Sanft.

We also are collaborating with Smoking cessation program and Yale palliative care program at the care center.

Extensive Research Description

Clinical trials.... see attached data of Clinical trial/ Investigator/ sub investigator

Clinical Research Working group

IRB oncology Yale University

Coauthors

Research Interests

Breast Neoplasms; Colonic Neoplasms; Lung Neoplasms; Lymphoma; Pancreatic Neoplasms

Selected Publications

  • HIV associated malignancy other than Hodgkin's lymphomaLichtman SM, Kaplan M, Zaheer W. HIV associated malignancy other than Hodgkin's lymphoma. Review Cancer (Madrid) 1994, 7(5):141-147
  • Mesenchymoma of liver: care report and review of literatureZaheer W, Allen SL, Ali SZ. Mesenchymoma of liver: care report and review of literature. Annals of Clinical and Laboratory Science 1994, 24(96):495-500
  • Endometrial adenocardinoma metastatic to bone diagnosed by fine needle aspiration biopsyAli SZ, Smilari AT, Zaheer W, Brones K. Endometrial adenocardinoma metastatic to bone diagnosed by fine needle aspiration biopsy. Journal of Surgical Pathology 1995, 1:137-141
  • Cervical cancer screening in the elderlyLichtman S, Zaheer W. Cervical cancer screening in the elderly. Primary Care and Cancer 1995, 15:21-22

Clinical Trials

ConditionsStudy Title
BreastRandomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer
BreastComparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial
LungIntegration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
LiverA Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)
Colon; RectumPhase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
LungMRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Colon; RectumRandomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Leukemia, otherA Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Non-Hodgkin's LymphomaA Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Efficacy of the Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-Cell Non-Hodgkin Lymphoma (NHL)
Other Female Genital; OvaryA Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
LungPhase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Multiple MyelomaA Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Corpus UteriA Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
Other Female GenitalA Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Colon; RectumTemozolomide and Olaparib for O6-Methylguanine DNA Methyltransferase Promoter Hypermethylated Colorectal Cancer
Hodgkin's LymphomaA Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
StomachPhase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer
Urinary BladderPhase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)
LiverA Phase 3 Double-Blinded, Two-Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
Multiple MyelomaDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)